Cargando…

In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril

Aim. Comparison of Captopril generic formulations on the Romanian market with the reference formulation Capoten (Bristol Myers Squibb), in terms of in vitro release kinetics of active substance and in vivo pharmacokinetics. Materials and methods. Dissolution studies were performed using Apparatus 1...

Descripción completa

Detalles Bibliográficos
Autores principales: ABDALRB, G.A., MIRCIOIU, I., AMZOIU, M., BELU, IONELA, ANUTA, VALENTINA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical University Publishing House Craiova 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284848/
https://www.ncbi.nlm.nih.gov/pubmed/30595878
http://dx.doi.org/10.12865/CHSJ.43.03.05
_version_ 1783379379343065088
author ABDALRB, G.A.
MIRCIOIU, I.
AMZOIU, M.
BELU, IONELA
ANUTA, VALENTINA
author_facet ABDALRB, G.A.
MIRCIOIU, I.
AMZOIU, M.
BELU, IONELA
ANUTA, VALENTINA
author_sort ABDALRB, G.A.
collection PubMed
description Aim. Comparison of Captopril generic formulations on the Romanian market with the reference formulation Capoten (Bristol Myers Squibb), in terms of in vitro release kinetics of active substance and in vivo pharmacokinetics. Materials and methods. Dissolution studies were performed using Apparatus 1 (Basket), DT 800H, Erweka, Germany in acidic medium (0.01 N hydrochloric acid) and an agitation speed of 50 rpm. Experiments were run on 12 tablets of each formulation. Quantification of Captopril was achieved by using a spectrophotometric method, λ=205nm. Clinical pharmacokinetics was determined in the frame of four different bioequivalence studies comparing a single dose four different Captopril 50mg generic tablet products to the innovator drug, Capoten 50mg (Bristol Myers Squibb). Results. Different batches of the reference formulations achieved dissolution profiles of the same form and very closed to each other at all dissolution points. Dissolution profiles of the tested formulations shown similar behavior for all references. Two generic formulations achieved a slower release at early dissolution time points, their release being “diffusion controlled”, described by law of Higuchi. In vivo, products proved to be bioequivalent, but variability of space distribution and forms of plasma profiles was much bigger than for the in vitro release curves. Due to very rapid in vitro dissolution, a direct Level A in vitro-in vivo correlation was not possible, but, strangely, the fraction absorbed vs. time clearly followed the same Higuchi law. Conclusion. All the studied formulations achieved more than 85% dissolution after 15 minutes which means that whatever the values of dissolution metrics f1 and f2, formulations behave like a solution and generally should not have therapeutic equivalence problems. Slower dissolution profiles correlates with in vivo absorption being described by the same square root law of Higuchi which describe diffusion controlled transport phenomena.
format Online
Article
Text
id pubmed-6284848
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medical University Publishing House Craiova
record_format MEDLINE/PubMed
spelling pubmed-62848482018-12-28 In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril ABDALRB, G.A. MIRCIOIU, I. AMZOIU, M. BELU, IONELA ANUTA, VALENTINA Curr Health Sci J Original Paper Aim. Comparison of Captopril generic formulations on the Romanian market with the reference formulation Capoten (Bristol Myers Squibb), in terms of in vitro release kinetics of active substance and in vivo pharmacokinetics. Materials and methods. Dissolution studies were performed using Apparatus 1 (Basket), DT 800H, Erweka, Germany in acidic medium (0.01 N hydrochloric acid) and an agitation speed of 50 rpm. Experiments were run on 12 tablets of each formulation. Quantification of Captopril was achieved by using a spectrophotometric method, λ=205nm. Clinical pharmacokinetics was determined in the frame of four different bioequivalence studies comparing a single dose four different Captopril 50mg generic tablet products to the innovator drug, Capoten 50mg (Bristol Myers Squibb). Results. Different batches of the reference formulations achieved dissolution profiles of the same form and very closed to each other at all dissolution points. Dissolution profiles of the tested formulations shown similar behavior for all references. Two generic formulations achieved a slower release at early dissolution time points, their release being “diffusion controlled”, described by law of Higuchi. In vivo, products proved to be bioequivalent, but variability of space distribution and forms of plasma profiles was much bigger than for the in vitro release curves. Due to very rapid in vitro dissolution, a direct Level A in vitro-in vivo correlation was not possible, but, strangely, the fraction absorbed vs. time clearly followed the same Higuchi law. Conclusion. All the studied formulations achieved more than 85% dissolution after 15 minutes which means that whatever the values of dissolution metrics f1 and f2, formulations behave like a solution and generally should not have therapeutic equivalence problems. Slower dissolution profiles correlates with in vivo absorption being described by the same square root law of Higuchi which describe diffusion controlled transport phenomena. Medical University Publishing House Craiova 2017 2017-09-28 /pmc/articles/PMC6284848/ /pubmed/30595878 http://dx.doi.org/10.12865/CHSJ.43.03.05 Text en Copyright © 2017, Medical University Publishing House Craiova http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
spellingShingle Original Paper
ABDALRB, G.A.
MIRCIOIU, I.
AMZOIU, M.
BELU, IONELA
ANUTA, VALENTINA
In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title_full In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title_fullStr In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title_full_unstemmed In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title_short In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril
title_sort in vitro and in vivo evaluation of different solid dosage forms containing captopril
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284848/
https://www.ncbi.nlm.nih.gov/pubmed/30595878
http://dx.doi.org/10.12865/CHSJ.43.03.05
work_keys_str_mv AT abdalrbga invitroandinvivoevaluationofdifferentsoliddosageformscontainingcaptopril
AT mircioiui invitroandinvivoevaluationofdifferentsoliddosageformscontainingcaptopril
AT amzoium invitroandinvivoevaluationofdifferentsoliddosageformscontainingcaptopril
AT beluionela invitroandinvivoevaluationofdifferentsoliddosageformscontainingcaptopril
AT anutavalentina invitroandinvivoevaluationofdifferentsoliddosageformscontainingcaptopril